Taylor Joseph Michael sold $278K of CBLL

Taylor Joseph Michael sold 10,200 shares of Ceribell, Inc. (CBLL) at $27.22 ($0.28M total) on 2026-11-09.

Original reporting
SEC EDGAR · Taylor Joseph Michael
Published Nov 10, 2026, 9:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 9:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CBLL
Bearish
medium confidence
Mentioned
$CBLL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CBLLBearishLow
01

Why it matters

The disclosed sale provides fresh, primary information but its modest size limits trading relevance.

02

Market read

A small insider sale that may cause slight short‑term pressure on CBLL.

03

What to watch

The director may have needed liquidity for personal reasons unrelated to the business.

Relevance 4/10Novelty 3/10Timing: post-market on 2026-11-09

Background

SEC Form 4 filing discloses an insider transaction by a Ceribell director.

Company-level read

Ticker impact

$CBLLBearishMedium confidence
Context

Director Taylor Joseph Michael sold 10,200 shares of Ceribell for $277,644 on 2026-11-09, reducing his holding to 38,278 shares.

Expected impact

potential slight downward pressure as the market prices the insider sell

Evidence & confidence

A $278K sale by a director is modest but may be interpreted as a negative signal by short‑term traders.

Market effects

Minimal impact on the broader medical device sector.

No significant regional effect.

Limited to Ceribell investors.

Counterpoint

The sale could be routine portfolio rebalancing and not reflect company fundamentals.

Key entities

  • Ceribell, Inc.

    Medical device company listed on Nasdaq under ticker CBLL.

  • Taylor Joseph Michael

    Director of Ceribell who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CBLLMedAI 8/10

CeriBell Inc (CBLL) (Q3 2026) Earnings Call Highlights: Record Hospital Additions

CeriBell Inc (CBLL) reported Q3 2026 revenue of $29.3M, up 30% YoY, with 35 new hospitals added. Gross margin improved to 90%, but net loss widened to $21.4M. Full-year guidance raised to $115-$117M. Delirium monitoring pilot showed clinical impact, but no material revenue contribution yet. Operating expenses rose 36% YoY. CEO Jane Chao and CFO Scott Blomberg discussed growth strategies and 2027 outlook.

$CBLLHigh

Ceribell Reports Third Quarter 2026 Financial Results

Ceribell, Inc. (CBLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Ceribell Reports Third Quarter 2026 Financial Results Sunnyvale, Calif. – November 3, 2026 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today repor

$EWHighAI 8/10

Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data

Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.

$CBLLMedAI 8/10

Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis

Ceribell, Inc. (Nasdaq: CBLL) received FDA 510(k) clearance for new software for its EEG system, enabling easier interpretation of brain activity trends. The update includes Alpha-Delta Ratio, Burst Suppression, and Amplitude-Integrated EEG monitoring, applicable to patients of all ages. The company expects to roll out the features in the first half of 2027.